Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,901 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M; Pasireotide C2305 Study Group. Colao A, et al. Among authors: gu f. J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. doi: 10.1210/jc.2013-2480. Epub 2014 Jan 13. J Clin Endocrinol Metab. 2014. PMID: 24423324 Free PMC article. Clinical Trial.
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, Shen CC, Gadelha M, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Freda P; Pasireotide C2305 Study Group. Bronstein MD, et al. Among authors: gu f. BMC Endocr Disord. 2016 Apr 2;16:16. doi: 10.1186/s12902-016-0096-8. BMC Endocr Disord. 2016. PMID: 27039081 Free PMC article. Clinical Trial.
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group. Pivonello R, et al. Among authors: gu f. Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014 Mar 27. Clin Endocrinol (Oxf). 2014. PMID: 24533697 Clinical Trial.
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly.
Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, van der Lely AJ, Ravichandran S, Kandra A, Pedroncelli AM, Colao AAL. Gadelha MR, et al. Among authors: gu f. Endocr Connect. 2020 Dec;9(12):1178-1190. doi: 10.1530/EC-20-0361. Endocr Connect. 2020. PMID: 33434154 Free PMC article.
A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group. Colao A, et al. Among authors: gu f. N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743. N Engl J Med. 2012. PMID: 22397653 Free article. Clinical Trial.
1,901 results